Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and Wegovy, plummeted this week. The company's stock price slid over eight percent on Thursday, following its main competitor in the space,  US-based pharmaceutical company Eli Lilly, announcing promising Phase 3 results of its GLP-1 pill orforglipron. The drug improved blood sugar levels in type 2 diabetes patients while helping them to lose weight, showing very similar benefits to injectable GLP-1 drugs. While Novo Nordisk has a terrible week, Eli Lilly shares shot up by 14 percent in light of the news, indicating investors were […]